Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Bernstein Liebhard LLP
NEW YORK, Dec. 19, 2013 /PRNewswire/ -- Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) that allege the blood-thinning medication caused patients to suffer life-threatening, uncontrollable bleeding continue to move forward in a multidistrict litigation underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to a Case Management Order issued on December 3, 2013, a schedule has been established that governs the production of text messages and other electronic and paper documents pertaining to discovery in bellwether cases. The first bellwether trial in the federal Pradaxa litigation is scheduled to begin in August 2014. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
"We are investigating Pradaxa lawsuits on behalf of individuals who allegedly suffered life-threatening hemorrhaging while using this blood thinner, and are monitoring this litigation very closely. We look forward to additional progress in the year ahead, as the proceeding moves closer to the first bellwether trial," says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of serious Pradaxa bleeding.
Pradaxa is a blood-thinning drug used to prevent strokes in people with atrial fibrillation. The medication was intended as an alternative to warfarin, a decades-old blood-thinner sold under the brand name Coumadin. However, while internal bleeding associated with warfarin can be stopped via the administration of vitamin k, there is no readily-available antidote to bring Pradaxa bleeding to an end.
In October, a report from the Institute for Safe Medicine Practices revealed that Pradaxa had been cited in more than 3,200 adverse event reports made to the U.S. Food & Drug Administration (FDA) in 2012. These included more than 580 reports that involved a patient death. By contrast, warfarin was cited in just 861 FDA adverse event reports, including 56 deaths.
According to court documents, 1,974 Pradaxa lawsuits are pending in the Southern District of Illinois on behalf of patients who allegedly suffered life-threatening episodes of Pradaxa bleeding. All of the lawsuits accuse Boehringer Ingelheim of failing to provide adequate warnings regarding the risk of serious hemorrhaging, including the lack of an antidote for such occurrences. The Court is scheduled to convene its next telephonic Status Conference on December 20, 2013.
Individuals who have allegedly suffered from Pradaxa bleeding may be entitled to file a claim against Boehringer Ingelheim seeking compensation for medical bills, lost wages, pain and suffering and other damages. To learn more about filing a Pradaxa lawsuit, please visit the Firm's website. Free, no-obligation case reviews may also be obtained by calling (888) 340-4807.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the "Plaintiffs' Hot List," recognizing the top plaintiffs' firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
©2012 PR Newswire. All Rights Reserved.